You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
The company raised $3.2 million in seed financing, which will go toward development of its platform and deployment of its flagship technology called VIPER.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The firm's nanotechnology-enabled, AI-based, machine learning tool identifies biomarkers in blood samples and produces results in 10 to 30 seconds.
The companies will pair Freenome's AI genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.
The partners will develop and implement bioinformatics tools, pipelines, and techniques to improve molecular profiling for research and clinical oncology.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.
In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.
In developing the new tools, Google trained artificial intelligence algorithms to aid pathologists in making breast and prostate cancer diagnoses.